Clever Leaves Holdings Inc. (CLVR) stock soared 5.65% in the after-hours trading session at the price of $6.73 despite no fundamental reason. In the last reported news, the company has scheduled to release its financial results for the third quarter of 2021. CLVR is an international cannabis company centered on large-scale cultivation, ecologically sustainable, and pharmaceutical-grade cannabinoid processing as the foundations of its cannabis market.
CLVR Scheduled Third Quarter 2021 Conference Call
On 27th October 2021, CLVR has scheduled to publish its financial results for the third quarter ended 30th September 2021. The management will hold a conference call on 10th November 2021, Wednesday, at 5:00 p.m. The company will also present its earnings report in a press release before the conference call. The webcast will be broadcast live and available on the company’s official website for replay.
CLVR Collaborated with Pharmalab PHL Laboratories
On 19th October 2021, CLVR published that it had commenced the commercial collaboration with Colombian-based Pharmalab PHL Laboratories. Pharmalab is a healthcare group that commercializes and distributes dietary supplements, medicines, and cosmetics. Under the deal, CLVR will provide cannabinoid formulations to Pharmalab to distribute magistral medications in Colombia. These drugs will use in the treatment of severe and inflammatory pathologies.
The collaboration was made achievable by the President Iván Duque Márquez’s recent signing of a Decree that enables drug dealers to sell and distribute magistral medicinal cannabinoids in Colombia. It is an essential move towards satisfying the unmet needs of Colombian patients.
Management Comments
President of CLVR, Andres Fajardo, remarked that this partnership is a remarkable opportunity to offer to Colombian patients, doctors, and health officials to meet their pharmaceutical quality standards. The company is distributing its cannabinoid products produced by Colombians, to Colombian patients. Their mutual aim to raise happier and healthier community standards makes Pharmalab the perfect partner, he concluded.
Director of Pharmalab, Mauricio Sierra, remarked that Pharmalab considers cannabinoid-based medicines as an effective supplement to address the adverse symptoms of various conditions. Their team is enthusiastic to begin commercial activities in the coming days, he added.
